Here is a novel use of ceftaroline to treat methicillin-resistant Staphylococcus epidermidis ventriculitis in a preterm infant with a ventriculosubgaleal shunt.
Key opinion leaders provide some advice for the public regarding COVID-19 booster shots and look to the future of the pandemic.
More treatment options and modalities are now available for patients.
This composite peptide vaccine targets key bacterial toxins to prevent sepsis, enhance antibiotic efficacy, reduce inflammation in diseases and cancer, with further data expected soon.
Risk of inaccuracy with pulse oximeters and clinician knowledge gaps in people of color may affect sepsis evaluations and impact treatment plans.
George Loukatos, MD, shares clinical pearls for the management of the SARS-CoV-2 and influenza viruses.
This pathogen is the third most frequently isolated nontuberculous mycobacteria seen in the United States. Here is a review of how it presents and treatment options.
In a long-acting dose regimen, an investigational antibodies treatment is a potent antiviral that can function as a component of a complete antiretroviral regimen.
The increasing presence of multiple non-AIDS comorbidities in women and others living with HIV challenges clinicians to steer away from the approach of optimizing individual chronic conditions but to think more holistically.
A research agenda focusing on breakthrough infections, reinfections, severity, and sequelae is needed to inform clinical practice when COVID-19 emphasis shifts from eradication to living with the disease.
Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.
By addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.
The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.
Despite advances in understanding and treating Long COVID, many questions about its mechanisms, susceptibility, and varied recovery patterns remain unresolved, underscoring the need for continued research.
In the second installment of a 3-part series on long-acting injectables related to various infections, Caitlin Soto, PharmD, BCIDP, provides insights on using rezafungin for invasive candidiasis.
Ongoing education and proven outcomes need to aid this form of testing.
This new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.
The continuation of misinformation and disinformation being disseminated in the public is causing more public health communication issues as mistruths associate the vaccines with cancer.
Clinicians look at optimal approaches for trying to avoid Clostridioides difficile infection (CDI).
The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.
Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.
This form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.
In the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.
Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.
Joseph Zackular, PhD highlights targeting high-risk groups for vaccination and shares insights into the future of mRNA vaccine development for C diff.
Outpatient parenteral antimicrobial therapy (OPAT) offers benefits for patients as well as providing cost effectiveness; however, it is not without its challenges. Two clinicians provide insights on this modality.
The recombinant human IgG1κ monoclonal antibody binds and neutralizes the virus.
With melting ice and the release of ancient viruses, there are concerns around the emergence of potentially unknown infectious diseases. Emily Jenkins PhD, DVM, BScHon, offers insights on “zombie viruses” and says polar bears might hold the key to understanding what lies ahead, and how a One Health approach may help in surveillance and prevention.